The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
It is developing the drug candidate to potentially treat immunological diseases
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Image and data analysis of rich spatial information from mIF images can accelerate tissue biomarker discovery and validation
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
The investigational prescription digital therapeutic uses a combination of sensors, software, and music based on Rhythmic Auditory Stimulation (RAS)
The FDA has determined that the known and potential benefits of the vaccine for the prevention of Covid-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved vaccines are not accessible
Subscribe To Our Newsletter & Stay Updated
